Apogee Therapeutics revealed on Wednesday that it has entered into a financing arrangement with Blackstone Life Sciences valued at as much as $1.3 billion. The capital is intended to fund late-stage development work and potential commercialization for zumilokibart, Apogee's experimental treatment for moderate-to-severe atopic dermatitis.
The structure of the deal consists of two elements: a royalty financing component of up to $800 million and access to up to $500 million in senior debt. Together those elements provide the company with a combined financing capacity of up to $1.3 billion to support continued development activities.
Apogee also released mid-stage clinical data for zumilokibart the same day. The trial enrolled 346 adults and, according to the company, the drug met all primary and secondary endpoints. Reported results indicate that after 16 weeks, 65.9% of participants receiving the mid-dose achieved at least a 75% improvement in eczema severity, while 61.6% of those on the higher dose reached the same threshold. By comparison, 23.4% of patients randomized to placebo achieved at least a 75% improvement.
Despite the positive efficacy readout reported by the company, Apogee's stock moved lower in premarket trading on the day of the announcement. Shares dropped nearly 12% following the financing disclosure and the release of the mid-stage data.
Context and focus
Zumilokibart is identified by Apogee as its lead candidate for the treatment of moderate-to-severe atopic dermatitis, a chronic skin condition. The newly arranged financing from Blackstone Life Sciences is designated to support the program through late-stage development and potentially into commercialization, subject to the company's plans and regulatory pathways.
Market reaction
Apogee reported a nearly 12% decline in its shares during premarket trading on the day the financing and trial results were disclosed.
Clinical trial snapshot
- Trial size: 346 adult participants.
- Key efficacy at 16 weeks: 65.9% response for mid-dose, 61.6% for high-dose, and 23.4% for placebo achieving at least a 75% improvement in eczema severity.
- Primary and secondary endpoints: reported as achieved by the company.
What this means for markets and sectors
The financing and clinical update touch on several market segments, including biotechnology and pharmaceuticals, as well as capital markets activity for small-cap drug developers. The royalty and debt components reflect funding approaches companies may use to support late-stage programs while managing balance sheet needs.